Literature DB >> 19236281

Evaluation of the effect of treatment of latent tuberculosis infection on QuantiFERON-TB gold assay results.

Nira R Pollock1, Suely S Kashino, Danielle R Napolitano, Alex Sloutsky, Swati Joshi, Jasmine Guillet, Michael Wong, Edward Nardell, Antonio Campos-Neto.   

Abstract

To evaluate the utility of the QuantiFERON-TB Gold assay for monitoring latent tuberculosis treatment efficacy, the assay was performed serially for healthcare workers receiving isoniazid therapy. After 9 months of isoniazid therapy, all of these healthcare workers remained QuantiFERON-TB Gold positive, and cellular proliferation assays revealed persistently strong purified protein derivative responses. These results do not support the use of the QuantiFERON-TB Gold assay to monitor therapy.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19236281      PMCID： PMC3571094          DOI： 10.1086/596606

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN： 0899-823X            Impact factor:   3.254


  9 in total

1.  Latent tuberculosis infection treatment and T-cell responses to Mycobacterium tuberculosis-specific antigens.

Authors:  Cynthia B E Chee; Kyi W KhinMar; Suay H Gan; Timothy M S Barkham; Mariappan Pushparani; Yee T Wang
Journal:  Am J Respir Crit Care Med       Date:  2006-11-02       Impact factor: 21.405

2.  Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis.

Authors:  Katie Ewer; Kerry A Millington; Jonathan J Deeks; Lydia Alvarez; Gerry Bryant; Ajit Lalvani
Journal:  Am J Respir Crit Care Med       Date:  2006-06-23       Impact factor: 21.405

3.  Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States.

Authors:  Gerald H Mazurek; John Jereb; Phillip Lobue; Michael F Iademarco; Beverly Metchock; Andrew Vernon
Journal:  MMWR Recomm Rep       Date:  2005-12-16

4.  Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005.

Authors:  Paul A Jensen; Lauren A Lambert; Michael F Iademarco; Renee Ridzon
Journal:  MMWR Recomm Rep       Date:  2005-12-30

5.  Identification of Mycobacterium tuberculosis ornithine carboamyltransferase in urine as a possible molecular marker of active pulmonary tuberculosis.

Authors:  Danielle R Napolitano; Nira Pollock; Suely S Kashino; Virmondes Rodrigues; Antonio Campos-Neto
Journal:  Clin Vaccine Immunol       Date:  2008-02-27

6.  Interferon-gamma responses after isoniazid chemotherapy for latent tuberculosis.

Authors:  Kazue Higuchi; Nobuyuki Harada; Toru Mori
Journal:  Respirology       Date:  2008-05       Impact factor: 6.424

7.  Effect of treatment of latent tuberculosis infection on the T cell response to Mycobacterium tuberculosis antigens.

Authors:  Katalin A Wilkinson; Onn M Kon; Sandra M Newton; Graeme Meintjes; Robert N Davidson; Geoffrey Pasvol; Robert J Wilkinson
Journal:  J Infect Dis       Date:  2005-12-29       Impact factor: 5.226

8.  Isoniazid prophylaxis differently modulates T-cell responses to RD1-epitopes in contacts recently exposed to Mycobacterium tuberculosis: a pilot study.

Authors:  Delia Goletti; M Pasquale Parracino; Ornella Butera; Federica Bizzoni; Rita Casetti; Duilio Dainotto; Gianfranco Anzidei; Carla Nisii; Giuseppe Ippolito; Fabrizio Poccia; Enrico Girardi
Journal:  Respir Res       Date:  2007-01-27

9.  Persistently elevated T cell interferon-gamma responses after treatment for latent tuberculosis infection among health care workers in India: a preliminary report.

Authors:  Madhukar Pai; Rajnish Joshi; Sandeep Dogra; Deepak K Mendiratta; Pratibha Narang; Keertan Dheda; Shriprakash Kalantri
Journal:  J Occup Med Toxicol       Date:  2006-05-23       Impact factor: 2.646
  9 in total
  10 in total

1.  Prevalence of tuberculosis infection and disease in children referred for tuberculosis medical surveillance in Ontario: a single-cohort study.

Authors:  Catherine Yang; Abdool S Yasseen; Jennifer Stimec; Elizabeth Rea; Valerie Waters; Ray Lam; Shaun K Morris; Ian Kitai
Journal:  CMAJ Open       Date:  2018-08-28

2.  Diagnosis and follow-up of treatment of latent tuberculosis; the utility of the QuantiFERON-TB Gold In-tube assay in outpatients from a tuberculosis low-endemic country.

Authors:  Anne M Dyrhol-Riise; Gerd Gran; Tore Wentzel-Larsen; Bjørn Blomberg; Christel Gill Haanshuus; Odd Mørkve
Journal:  BMC Infect Dis       Date:  2010-03-08       Impact factor: 3.090

3.  Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers.

Authors:  Felix C Ringshausen; Albert Nienhaus; Anja Schablon; Stephan Schlösser; Gerhard Schultze-Werninghaus; Gernot Rohde
Journal:  BMC Infect Dis       Date:  2010-07-23       Impact factor: 3.090

4.  Detection of Mycobacterium tuberculosis complex DNA in CD34-positive peripheral blood mononuclear cells of asymptomatic tuberculosis contacts: an observational study.

Authors:  Mulugeta Belay; Begna Tulu; Sidra Younis; David A Jolliffe; Dawit Tayachew; Hana Manwandu; Tenagnework Abozen; Emawayish A Tirfie; Metasebia Tegegn; Aboma Zewude; Sally Forrest; Jonathan Mayito; Jim F Huggett; Gerwyn M Jones; Denise M O'Sullivan; Henny M Martineau; Mahdad Noursadeghi; Aneesh Chandran; Kathryn A Harris; Vlad Nikolayevskyy; Julie Demaret; Stefan Berg; Martin Vordermeier; Taye T Balcha; Abraham Aseffa; Gobena Ameni; Markos Abebe; Stephen T Reece; Adrian R Martineau
Journal:  Lancet Microbe       Date:  2021-06

5.  Within-subject interlaboratory variability of QuantiFERON-TB gold in-tube tests.

Authors:  William C Whitworth; Lanette R Hamilton; Donald J Goodwin; Carlos Barrera; Kevin B West; Laura Racster; Laura J Daniels; Stella O Chuke; Brandon H Campbell; Jamaria Bohanon; Atheer T Jaffar; Wanzer Drane; David Maserang; Gerald H Mazurek
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

Review 6.  Assessing tuberculosis case fatality ratio: a meta-analysis.

Authors:  Masja Straetemans; Philippe Glaziou; Ana L Bierrenbach; Charalambos Sismanidis; Marieke J van der Werf
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

7.  Effect of isoniazid on antigen-specific interferon-γ secretion in latent tuberculosis.

Authors:  Martha Torres; Lourdes García-García; Pablo Cruz-Hervert; Heinner Guio; Claudia Carranza; Leticia Ferreyra-Reyes; Sergio Canizales; Susana Molina; Elizabeth Ferreira-Guerrero; Norma Téllez; Rogelio Montero-Campos; Guadalupe Delgado-Sánchez; Norma Mongua-Rodriguez; Jose Sifuentes-Osornio; Alfredo Ponce-de Leon; Eduardo Sada; Douglas B Young; Robert J Wilkinson
Journal:  Eur Respir J       Date:  2014-10-30       Impact factor: 16.671

8.  Factoring Prior Treatment into Tuberculosis Infection Prevalence Estimates, United States, 2011-2012.

Authors:  Laura A Vonnahme; Maryam B Haddad; Thomas R Navin
Journal:  Emerg Infect Dis       Date:  2019-10       Impact factor: 6.883

9.  A differential DNA methylome signature of pulmonary immune cells from individuals converting to latent tuberculosis infection.

Authors:  Lovisa Karlsson; Jyotirmoy Das; Moa Nilsson; Amanda Tyrén; Isabelle Pehrson; Nina Idh; Shumaila Sayyab; Jakob Paues; Cesar Ugarte-Gil; Melissa Méndez-Aranda; Maria Lerm
Journal:  Sci Rep       Date:  2021-09-30       Impact factor: 4.379

10.  Variability of the QuantiFERON®-TB gold in-tube test using automated and manual methods.

Authors:  William C Whitworth; Donald J Goodwin; Laura Racster; Kevin B West; Stella O Chuke; Laura J Daniels; Brandon H Campbell; Jamaria Bohanon; Atheer T Jaffar; Wanzer Drane; Paul A Sjoberg; Gerald H Mazurek
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.